JOINN Laboratories China Purchases Provantis
10 January 2013
Instem plc
("Instem", the "Company" or the "Group")
JOINN Laboratories China Purchases Provantis
Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces today that JOINN Laboratories (JOINN) has purchased its Provantis® preclinical software solution suite to automate processes within its China-based facilities located in Beijing and Suzhou.
JOINN provides drug screening, efficacy studies, pharmacokinetics studies, safety evaluations, clinical trials and final drug registration services. Founded in 1995, JOINN was China’s first preclinical laboratory to be inspected by the U.S. Food and Drug Administration (FDA) for Good Laboratory Practice (GLP) compliance, and now supports clients from more than 20 provinces across China, Japan and Europe. Within the United States, JOINN provides international clients with technical consulting services for FDA drug registration.
Following a comprehensive evaluation of software technologies, Instem was selected due to its presence and experience within China and its leading position in the global early development safety assessment market. Utilising Provantis, JOINN will further improve the quality of its study processes and deliver demonstrable efficiency improvements in support of its mission to provide services for drug innovation to benefit worldwide public health.
Provantis is a modern, fully integrated software system for single users and global organisations engaged in preclinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple or complex studies within a GLP or non-GLP environment, on-site or over the Web.
Phil Reason, CEO of Instem plc, commented: “We are delighted to welcome JOINN, China’s largest provider of preclinical studies, to the Instem client community. Their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the longer term growth potential in what is already the third largest pharmaceutical market in the world.”
For further information, please contact:
| Instem plc | www.instem.com |
| Phil Reason, CEO | +44 (0) 1785 825600 |
| Nigel Goldsmith, CFO | |
| N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| Richard Lindley | |
| Nick Owen | |
| James White | |
| Wallbrook Financial PR | Tel: +44 (0) 20 7933 8000 |
| Paul Cornelius | or instem@walbrookpr.com |
| Sam Allen | |
| Helen Cresswell | |
| Paul Whittington |
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.